TBPH - テラバンス・バイオファ―マ （Theravance Biopharma Inc.）TBPHのニュース
Top Healthcare Stocks for April 2023 2023/03/30 21:22:28 Investopedia
Top healthcare stocks include Theravance Biopharma for best value, ShockWave Medical for fastest growth, and Ardelyx for most momentum.
Top Healthcare Stocks for March 2023 2023/03/08 19:50:22 Investopedia
Top healthcare stocks include Theravance Biopharma for best value, Signify Health for fastest growth, and TransMedics Group for most momentum.
Theravance Biopharma, Inc. 2022 Q4 - Results - Earnings Call Presentation 2023/03/08 19:09:19 Seeking Alpha
The following slide deck was published by Theravance Biopharma, Inc.
Theravance Biopharma Inc. (TBPH) Q4 2022 Earnings Call Transcript 2023/02/28 02:25:20 Seeking Alpha
Theravance Biopharma Inc. (NASDAQ:NASDAQ:TBPH) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ETCompany ParticipantsRick Winningham - Chairman and Chief Executive OfficerRhonda…
Theravance Biopharma Q4 results mixed, co to reduce headcount by about 17% 2023/02/27 21:24:29 Seeking Alpha
Theravance Biopharma press release (TBPH): Q4 GAAP EPS of -$0.15 beats by $0.02.Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M.Discontinuing investments in research, reducing…
Theravance Biopharma Inc. (TBPH) Q4 2022 Earnings Call Transcript 2023/02/28 02:25:20 Seeking Alpha
Theravance Biopharma Inc. (NASDAQ:NASDAQ:TBPH) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ETCompany ParticipantsRick Winningham - Chairman and Chief Executive OfficerRhonda…
Theravance Biopharma Q4 results mixed, co to reduce headcount by about 17% 2023/02/27 21:24:29 Seeking Alpha
Theravance Biopharma press release (TBPH): Q4 GAAP EPS of -$0.15 beats by $0.02.Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M.Discontinuing investments in research, reducing…
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update 2023/02/27 21:05:00 PR Newswire
Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments in research, reducing headcount by approximately 17% Reports highest quarter of YUPELRI (revefenacin) net sales and profitability…
Earnings Preview: Theravance Biopharma 2023/02/24 20:02:25 Benzinga
Theravance Biopharma (NASDAQ: TBPH ) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here''s what investors need to know before the announcement. Analysts estimate that Theravance Biopharma will report an earnings per share (EPS) of $-0.17. Theravance Biopharma bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 2023/02/21 11:00:00 PR Newswire
DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023. An accompanying conference call and simultaneous webcast will…
Theravance Biopharma to Participate in an Upcoming Investor Conference 2023/02/09 11:00:00 PR Newswire
DUBLIN, Feb. 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 8:00 am ET (5:00 am PT/1:00 pm GMT). Webcast of the event may be accessed by visiting…
Investing in Theravance Biopharma Inc. (TBPH) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/16 18:24:00 US Post News
A share of Theravance Biopharma Inc. (NASDAQ:TBPH) closed at $11.30 per share on Friday, up from $11.02 day before. While Theravance Biopharma Inc. has overperformed by 2.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TBPH rose by 18.82%, with highs and lows ranging from $11.83 […]
Investing in Theravance Biopharma Inc. (TBPH) might be a great opportunity, but the stock is a bit overvalued 2022/12/05 14:40:00 US Post News
In Friday’s session, Theravance Biopharma Inc. (NASDAQ:TBPH) marked $11.02 per share, up from $10.80 in the previous session. While Theravance Biopharma Inc. has overperformed by 2.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TBPH rose by 34.55%, with highs and lows ranging from $13.17 to […]
Do investors need to be concerned about Theravance Biopharma Inc. (TBPH)? 2022/11/25 13:32:00 US Post News
In Wednesday’s session, Theravance Biopharma Inc. (NASDAQ:TBPH) marked $10.27 per share, down from $10.61 in the previous session. While Theravance Biopharma Inc. has underperformed by -3.20%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TBPH rose by 21.54%, with highs and lows ranging from $13.17 to […]
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer | MarketScreener 2022/11/18 11:01:04 MarketScreener
DUBLIN, Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. today announced the preliminary results of its Dutch auction tender offer to purchase up to $95 million of its ordinary shares,… | November 18, 2022